NCT05757245View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

August 1, 2028

Study Completion Date

December 31, 2030

Conditions
Transfusion-dependent α-Thalassemia
Interventions
GENETIC

GMCN-508A Drug Product

Transplant of autologous hematopoietic stem and progenitor cells transduced with GMCN-508A lentiviral vector.

Trial Locations (1)

530021

RECRUITING

The affiliated hospital of guangxi medical university, Nanning

Sponsors

Collaborators (1)

Genmedicn Biopharma Ltd.
All Listed Sponsors
collaborator

Genmedicn Biopharma Ltd.

UNKNOWN

lead

First Affiliated Hospital of Guangxi Medical University

OTHER

NCT05757245 - A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants | Biotech Hunter | Biotech Hunter